BioCryst's BCX7353 reduces HAE attacks in Phase II

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said 2 of 3 dose levels of oral BCX7353 significantly reduced mean hereditary angioedema (HAE) attacks during weeks 2 through 4 of the double-blind, international Phase II APeX-1 trial to prevent attacks in patients with HAE.

The interim analysis pooled data from patients in the 3-part trial’s first and second parts. In 44 patients in the per protocol (PP) population, once-daily 125, 250 and 350 mg BCX7353 for 28 days led to mean HAE attack reductions of 73% (p=0.002), 37% (p=0.128) and 58% (p=0.001), respectively, vs. placebo. In 51 patients in the intent-to-treat (ITT) population, low-, mid- and high-dose BCX7353 led to mean HAE attack reductions of 73% (p=0.004), 44% (p=0.09) and 45% (p=0.014), respectively, vs. placebo...